Biotech Values

[xavierprivas]

I was using Cellectis as an example of real threat to Kite, Juno
if (big if) Cellectis works. I don't want to make it look like a
recommendation for Cellectis.

I don't have any position in Kite, Juno either because of their valuation and
it is not clear that it will work in solid tumor. Hematologic cancer
is a very competitive market.

As for Cellectis, there is no data initially so I pass. After that one
case was published, the stock jumped so I decided to pass.

My method of investing is to look for real positive data then wait until
price drops for no good reason. Like now I loaded on FGEN
(thanks to biomaven) and EGRX (thanks to Dew).

In my estimate EGRX can turn a profit this year rare for a biotech and
nothing has changed since the stock peaked in Dec around $105. Below
$70 yesterday, quite a bargain.

The market is not very rational or efficient (just like Dew signature)